Discover
OTLK
Outlook Therapeutics, Inc.
0.60
2 x 0.42
1 x 0.60
bid
ask
+
0.03
6.19%
2 @ 06:42 PM
0.60 +0.00 (0.02%)
| Ytd | -62.09% | |
| 1y | -51.31% |
0.56
day range
0.60
0.20
52 week range
2.47
| Open | 0.57 | Prev Close | 0.56 | Low | 0.56 | High | 0.60 | Mkt Cap | 145.80M |
| Vol | 3.69M | Avg Vol | 13.33M | EPS | -0.70 | P/E | N/A | Forward P/E | -0.55 |
| Beta | 0.63 | Short Ratio | 1.26 | Inst. Own | 35.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.73 | 200-d Avg | 0.71 | 1yr Est | 24.80 |
OTLK News
globenewswire.com
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. c
globenewswire.com
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Compan
Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Compan
benzinga.com
Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthc
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development an
benzinga.com
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and